

1. **[Coming soon: Tax sops, loans for cos to boost IPR](#)** – Times of India

The government is ready with the country's first intellectual property rights (IPR) policy that has suggested a series of tax sops and other incentives to promote research and development and patents, besides providing support to small and medium enterprises and start-ups.

At the same time, the cabinet note moved by the department of industrial policy and promotion (DIPP), has said the government would use the legislative space and flexibility available under international treaties such as TRIPs to protect its interests.

1. **[Coming soon: Tax sops, loans for cos to boost IPR](#)** – Times of India

2. **[Medical devices to be delinked from pharma industry soon](#)** – Hindu Business Line

3. **[Separate ministry for pharma in next one year: Ananth Kumar](#)** – Economic Times

4. **[The case for shifting of IPR cases](#)** – Financial Express

5. **[PRICE FIXING OF DEVICES](#)** – Pharmabiz

2. **[Medical devices to be delinked from pharma industry soon](#)** – Hindu Business Line

The Modi government is set to delink the medical device industry from the pharmaceutical sector, giving a major push for 'Make in India' in the medical device sector, according to people privy to the development.

The decision to create separate rules for device makers, in line with global standards, was taken after a meeting of senior officials of the Ministry of Health & Family Welfare and the Central Drugs Standard Control Organisation (CDSCO) with industry representatives including the Association of Indian Medical Device Industry (AIMED), people attending the meeting told BusinessLine.

India currently imports 70 per cent of its medical devices. The size of the market is estimated at over \$10 billion at retail level sales.

Also appeared in [Business Today](#) and [Pharmabiz](#)

3. **[Separate ministry for pharma in next one year: Ananth Kumar](#)** – Economic Times

Union Fertilisers Minister Ananth Kumar today said there will be a separate ministry for pharma and medical devices sector in the next one year, and assured that the government will soon implement the Katoch panel recommendations to cut bulk drugs import from China.

He added that the government recognises the pharma sector as a 'sunshine industry' having a tremendous potential for growth.

Kumar said that in order to benefit the domestic pharma industry, the government plans to implement the recommendations by the Katoch Committee in the next 100 days.

Also appeared in [New Indian Express](#), [Business Standard](#)

4. **[The case for shifting of IPR cases](#)** – Financial Express

The Delhi High Court has stayed the transfer of pending intellectual property rights (IPR) disputes to the 12 district courts irrespective of their pecuniary value. It said it will wait till further clarity in law emerges.

The Delhi High Court (Amendment) Act, which came into effect from October 26, was enacted with the objective to reduce the workload of the Court by distributing this burden to lower courts.

They sought quashing of the Court's administrative order that had allowed a transfer of all pending cases up to the value of Rs 1 crore to subordinate courts. They said cases arising out of the statutes relating to IPR were "protected" under the 2015 ordinance.

5. **PRICE FIXING OF DEVICES** – Pharmabiz

The government has been contemplating to bring some price control on critical medical devices in the country from last year in the context of repeated complaints of overcharging of these products by the patient groups. The MNCs have been freely importing and selling medical devices either directly or through their agents at exorbitant prices and making huge profits with the support of hospital managements and medical professionals as hardly 30 per cent of this class of products are indigenously produced.

As a first step to have some regulatory control on this class of products, the government had classified 14 medical devices like cardiac stents, drug eluting stents, orthopaedic implants, etc. as drugs and placed them under Drugs & Cosmetics Act some time ago. But these products still remained outside any price control. And only in last April, a Task Force, set up by the Department of Pharmaceuticals (DoP), recommended framing of a separate price control order for medical devices and placing them under the Essential Commodities Act.